<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prurigo nodularis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prurigo nodularis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prurigo nodularis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kalman Watsky, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H21099279"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prurigo nodularis (PN) is an uncommon, chronic skin disorder affecting primarily older adults and is characterized by symmetrically distributed, multiple, firm, pruritic nodules  (<a class="graphic graphic_picture graphicRef116912 graphicRef116913" href="/z/d/graphic/116912.html" rel="external">picture 1A-B</a>). PN occurs in patients with chronic pruritus and is frequently associated with a history of atopic dermatitis [<a href="#rid1">1-3</a>].</p><p>PN will be discussed in this topic. Chronic pruritus and other skin conditions associated with chronic pruritus and papulonodular skin lesions, including scabies and lichen planus, and acquired perforating dermatoses are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/108935.html" rel="external">"Perforating dermatoses", section on 'Acquired perforating dermatosis'</a>.)</p><p></p><p class="headingAnchor" id="H21099286"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The exact incidence and prevalence of PN are not known. In the United States, the estimated prevalence is 72 per 100,000 persons [<a href="#rid4">4</a>]. PN can occur in all age groups without sex predilection but primarily affects older adults [<a href="#rid5">5,6</a>]. In a review of 108 cases of PN, the median age was 62 years [<a href="#rid5">5</a>]. In the United States, PN seems to be more common among African Americans than in other ethnic groups. In a single-institution study including 909 patients with PN, African American patients were 3.4 times more likely to have PN than White patients (odds ratio [OR] 3.4, 95% CI 2.9-3.9) [<a href="#rid7">7</a>].</p><p>PN occurs in approximately 5 percent of patients with human immunodeficiency virus (HIV) infection [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H21099293"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>PN is a distinctive reaction pattern occurring in a subset of patients with chronic pruritus, as a result of continuous scratching over a prolonged period of time. Predisposing factors include dermatologic, systemic, neurologic, and psychiatric diseases associated with severe pruritus.</p><p>However, the exact pathogenesis of PN remains unclear. The following pathogenetic mechanisms have been hypothesized:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased number of nerve fibers in the papillary dermis</strong> – Earlier studies noted an increased number of nerve fibers in the papillary dermis, suggesting a neurocutaneous component in the pathogenesis of PN [<a href="#rid10">10</a>]. Nerve growth factor (NGF) and its receptor, tyrosine kinase A (TrkA), are overexpressed in PN lesions and may be associated with the increased release and accumulation of neuropeptides, such as substance P and calcitonin gene-related peptide [<a href="#rid11">11-13</a>]. Mast cells, which are known to release NGF, are seen in close vicinity to nerves expressing TrkA [<a href="#rid14">14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous small fiber neuropathy</strong> – Subsequent studies have noted a hypoplasia of intraepidermal nerves in PN. An immunohistochemical study of 53 patients with PN found that intraepidermal nerve fiber density is reduced in lesional and nonlesional skin of patients with PN. A subsequent study of 30 patients with PN confirmed a significant reduction of intraepidermal nerve fiber density in lesional and perilesional skin compared with normal and healed skin. These findings suggest that PN may represent a form of subclinical, cutaneous small fiber neuropathy [<a href="#rid16">16-18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Th2 cytokines</strong> – The role of T helper 1 (Th1) and T helper 2 (Th2) cytokines in the pathogenesis of PN also has been evaluated by examining the cytokine signatures in the epidermis in 22 cases of PN, using the signal transducers and activators of transcription (STAT) 1, 3, and 6 [<a href="#rid19">19</a>]. In 19 of 22 cases, the entire epidermis stained with anti-pSTAT 6, a marker for the Th2 cytokines interleukin (IL) 4, IL-5, and IL-13. Only eight cases showed scattered staining with anti-pSTAT 1, a marker for the Th1 cytokines interferon-gamma and IL-27. These findings suggest that Th2 cytokines play a principal role in the pathogenesis of PN.</p><p></p><p class="bulletIndent1">A transcriptome analysis of lesional PN skin and blood immunophenotyping demonstrated circulating and cutaneous T helper type 22 (Th22) immune dysregulation skewed toward a Th22/IL-22 profile [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">A proteomic analysis of plasma from patients with PN showed increased levels of inflammatory markers, including tumor necrosis factor (TNF), chemokine ligand (CXCL), IL-12B, IL-18, monocyte chemotactic protein, and TNF receptor superfamily member 9, compared with healthy controls [<a href="#rid21">21</a>]. The inflammatory protein profile also identified two clinically distinct clusters of patients with PN, one characterized by younger age and higher prevalence of myelopathy and the other characterized by higher prevalence of atopic dermatitis.</p><p></p><p class="bulletIndent1">Aberrant expression of IL-31, a potent pruritogenic cytokine preferentially expressed by CD4+ Th2 cells, and other nonhistamine pruritogenic mediators, including NGF, thymic stromal lymphopoietin, and endothelin, has been described in PN lesions [<a href="#rid22">22,23</a>]. The receptor for IL-31, made up of two subunits (IL-31 receptor A [IL-31RA] and oncostatin M receptor-beta), is expressed on sensory neurons, keratinocytes, and myeloid cells. IL-31RA, expressed on a subset of small C-fiber neurons that innervate the skin from the dorsal root ganglion, is targeted by nemolizumab, a humanized monoclonal antibody.</p><p></p><p class="bulletIndent1">Analysis of serum proteins comparing nemolizumab responders with nonresponders from a phase 2 trial showed downregulation of cytokines in the IL-6 family, which includes IL-31, confirming its role in the pathogenesis of at least some subtypes of PN [<a href="#rid24">24</a>].</p><p></p><p class="headingAnchor" id="H6984368"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>The histopathology of PN shows:</p><p class="bulletIndent1"><span class="glyph">●</span>Thick, compact orthohyperkeratosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Irregular epidermal hyperplasia or pseudoepitheliomatous hyperplasia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal parakeratosis with irregular acanthosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diminished nerve fiber density.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A nonspecific dermal infiltrate containing lymphocytes, macrophages, eosinophils, and neutrophils  (<a class="graphic graphic_picture graphicRef86963" href="/z/d/graphic/86963.html" rel="external">picture 2</a>) [<a href="#rid25">25-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A hair follicle may be seen in the center of the lesion [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H21099300"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>PN typically presents with firm, dome-shaped, itchy nodules ranging in size from a few millimeters to several centimeters and often symmetrically distributed on the extensor surfaces of the arms and legs and on the trunk  (<a class="graphic graphic_picture graphicRef116912 graphicRef116913 graphicRef86816 graphicRef66268 graphicRef53475 graphicRef86964" href="/z/d/graphic/116912.html" rel="external">picture 1A-F</a>). Nodules can be flesh-colored, erythematous, or brown/black and range in number from few to hundreds  (<a class="graphic graphic_picture graphicRef116913 graphicRef86817" href="/z/d/graphic/116913.html" rel="external">picture 1B, 1G</a>).</p><p>The extensor surfaces of the extremities are characteristically involved, but the upper back, abdomen, and sacrum can also be involved. The difficult-to-reach upper midback area is usually spared ("butterfly" sign  (<a class="graphic graphic_picture graphicRef130452" href="/z/d/graphic/130452.html" rel="external">picture 3</a>)) [<a href="#rid28">28</a>]. The palms, soles, face, and flexural areas are rarely involved.</p><p>Pruritus is always severe and distressing; it can be paroxysmal, sporadic, or continuous and is worsened by heat, sweating, or irritation from clothing. In many cases, the cause of pruritus is unknown. In a multicenter, cross-sectional, European study of 509 patients with PN, 71 percent of patients experience itch often or always and 53 percent reported that their daily life was negatively affected [<a href="#rid30">30</a>].</p><p>In some patients, a coexistent pruritic skin condition (eg, atopic dermatitis, xerosis) may be the initial cause of pruritus. Rarely, PN may be the presenting symptom of a systemic disease, such as infection with HIV or mycobacteria, parasitic infestation, or lymphoma [<a href="#rid9">9,31-34</a>].</p><p>A clinical presentation characterized by the coexistence of prurigo nodules and multiple keratoacanthomas on pruritic, actinically damaged skin has been described in several patients [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/13718.html" rel="external">"Keratoacanthoma: Epidemiology, risk factors, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2338027850"><span class="h1">ASSOCIATED CONDITIONS</span><span class="headingEndMark"> — </span>Approximately half of all cases of PN have a history of atopic dermatitis [<a href="#rid5">5</a>]. These patients may have PN at an earlier age than nonatopic patients [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p>Systemic diseases (eg, diabetes, chronic renal failure, cardiovascular disease, hepatitis C, gluten enteropathy, HIV infection), psychiatric disorders (eg, anxiety, depression), sleep disorders, and emotional stress have also been reported with high frequency in patients with PN [<a href="#rid5">5,7,37-42</a>]. PN occurs in approximately 5 percent of patients with HIV infection, particularly among individuals with a CD4+ count &lt;200 cells/mm<sup>3</sup> [<a href="#rid8">8,9</a>]. However, the exact role of these underlying conditions in the development of PN is unclear.</p><p>PN has also been associated with other conditions associated with alterations in central nervous system pain processing, such as fibromyalgia, interstitial cystitis/bladder pain syndrome, and irritable bowel syndrome. In an analysis of data on hospitalized patients from the National Inpatient Sample that included nearly 1500 patients with PN, patients with PN had increased odds of having fibromyalgia (odds ratio [OR] 3.38, 95% CI 2.78-4.10), interstitial cystitis/bladder pain syndrome (OR 24.40, 95% CI 19.42-30.64), and irritable bowel syndrome (OR 2.10, 95% CI 1.52-2.90) [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H21099314"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of PN is clinical, based upon a history of chronic, severe pruritus and the clinical finding of characteristic excoriated, nodular lesions often symmetrically distributed  (<a class="graphic graphic_picture graphicRef86817 graphicRef53475 graphicRef66268 graphicRef86816" href="/z/d/graphic/86817.html" rel="external">picture 1C-E, 1G</a>) [<a href="#rid44">44</a>]. A skin biopsy is not routinely performed to confirm the diagnosis. </p><p>However, a skin biopsy may be indicated in cases where the clinical diagnosis is in question or there is a poor response to first-line therapies. Immunofluorescence studies and enzyme-linked immunosorbent assay to detect the presence of circulating autoantibodies against bullous pemphigoid may be performed if suggested by history and clinical examination. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>In patients with PN who do not have a history of atopic dermatitis or other pruritic skin conditions, systemic causes of chronic pruritus (eg, chronic kidney disease, liver disease, thyroid disease, HIV infection, parasitic infestation, malignancy) should be investigated. The initial laboratory and imaging evaluation may include (see  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood cell count</p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests</p><p class="bulletIndent1"><span class="glyph">●</span>Blood urea nitrogen and creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid-stimulating hormone</p><p class="bulletIndent1"><span class="glyph">●</span>HIV test</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis</p><p class="bulletIndent1"><span class="glyph">●</span>Stool examination for ova and parasites</p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph</p><p></p><p class="headingAnchor" id="H6984633"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Skin diseases that may mimic PN include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired reactive perforating dermatoses</strong> – Acquired reactive perforating dermatoses are a group of rare skin disorders most commonly associated with chronic renal failure and diabetes mellitus, characterized by transepithelial elimination of dermal material. They present with pruritic, dome-shaped, umbilicated papules with a central keratinous plug located on the trunk and limbs  (<a class="graphic graphic_picture graphicRef86478 graphicRef86829 graphicRef86830 graphicRef86831" href="/z/d/graphic/86478.html" rel="external">picture 4A-D</a>) [<a href="#rid45">45</a>]. Histology reveals a cup-shaped depression of the epidermis filled with a plug consisting of keratin, collagen, and inflammatory debris. The underlying epidermis shows fine slits through which basophilic collagen fibers in vertical orientation are extruded. (See  <a class="medical medical_review" href="/z/d/html/108935.html" rel="external">"Perforating dermatoses", section on 'Acquired perforating dermatosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pemphigoid nodularis</strong> – Pemphigoid nodularis is a rare variant of bullous pemphigoid (BP) characterized by pruritic nodules, papules, or plaques that mimic PN clinically and histologically [<a href="#rid26">26,46</a>]. The diagnosis is confirmed by direct immunofluorescence, showing linear immunoglobulin G (IgG) and/or complement component 3 (C3) staining along the basement membrane zone, and presence of circulating autoantibodies against BP antigens [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nodular scabies</strong> – A history of exposure and histologic examination can usually differentiate PN from nodular scabies  (<a class="graphic graphic_picture graphicRef60849 graphicRef75169 graphicRef83093" href="/z/d/graphic/60849.html" rel="external">picture 5A-C</a>). Usually, other typical signs of scabies, such as burrows and excoriations, are present. (See  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertrophic lichen planus</strong> – Hypertrophic lichen planus is a variant of lichen planus characterized by the presence of thick, hyperkeratotic plaques, often on the anterior aspect of the legs  (<a class="graphic graphic_picture graphicRef54396" href="/z/d/graphic/54396.html" rel="external">picture 6</a>). Histology can clarify the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple keratoacanthomas</strong> – Multiple keratoacanthomas are a feature of several rare familial or sporadic disorders  (<a class="graphic graphic_table graphicRef76410" href="/z/d/graphic/76410.html" rel="external">table 1</a>), including Ferguson-Smith syndrome and Grzybowski syndrome  (<a class="graphic graphic_picture graphicRef50780" href="/z/d/graphic/50780.html" rel="external">picture 7</a>) [<a href="#rid48">48</a>]. The absence of pruritus, histologic features, and clinical course differentiate multiple keratoacanthomas from PN. (See  <a class="medical medical_review" href="/z/d/html/13718.html" rel="external">"Keratoacanthoma: Epidemiology, risk factors, and diagnosis", section on 'Multiple keratoacanthomas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidermolysis bullosa pruriginosa</strong> – Epidermolysis bullosa (EB) pruriginosa is a rare, localized variant of dystrophic EB characterized by skin fragility, intense pruritus, and skin lesions resembling hypertrophic lichen planus or PN [<a href="#rid49">49,50</a>]. The clinical suspicion of inherited EB needs to be confirmed by appropriate immunofluorescence studies. (See  <a class="medical medical_review" href="/z/d/html/15449.html" rel="external">"Epidermolysis bullosa: Epidemiology, pathogenesis, classification, and clinical features", section on 'Rare subtypes'</a>.)</p><p></p><p class="headingAnchor" id="H2648390708"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment of PN is difficult and requires a multifaceted approach, involving [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient education to adopt general measures to reduce skin irritation and scratching</p><p class="bulletIndent1"><span class="glyph">●</span>Symptomatic treatment of pruritus</p><p class="bulletIndent1"><span class="glyph">●</span>Topical or systemic therapies aimed at interrupting the itch-scratch cycle and flattening the skin lesions</p><p></p><p>Topical and systemic therapies for PN have not been adequately evaluated in randomized trials. Evidence for their use is based upon a few small, randomized trials; small case series; and clinical experience [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H4003445471"><span class="h2">Symptomatic control of pruritus</span><span class="headingEndMark"> — </span>In patients with PN, gentle skin care using mild cleansers for bathing or showering and applying emollients multiple times per day to soothe the skin and reduce dryness should be encouraged. Additional relief can be provided by lotions that provide a cooling sensation on the skin, such as <a class="drug drug_general" data-topicid="16451" href="/z/d/drug information/16451.html" rel="external">calamine lotion</a> or lotions containing menthol and <a class="drug drug_general" data-topicid="104178" href="/z/d/drug information/104178.html" rel="external">camphor</a>, and those containing <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">pramoxine</a> hydrochloride, a local anesthetic.</p><p>To minimize the consequences of scratching and avoid excoriations, patients should keep their nails short and may wear gloves at night. Occluding the involved areas with bandages (eg, <a class="drug drug_general" data-topicid="10056" href="/z/d/drug information/10056.html" rel="external">Unna boot</a>) or dressings may provide further relief. (See  <a class="medical medical_review" href="/z/d/html/15199.html" rel="external">"Compression therapy for the treatment of chronic venous insufficiency", section on 'Unna boot'</a>.)</p><p>Any underlying compulsive behavior (eg, skin picking) should be treated. (See  <a class="medical medical_review" href="/z/d/html/13698.html" rel="external">"Skin picking (excoriation) disorder and related disorders", section on 'General considerations'</a>.)</p><p>Pharmacologic therapy with first-generation sedating antihistamines (eg, <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a>, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>) administered at bedtime may be useful in controlling nocturnal pruritus. Both selective serotonin reuptake inhibitors and tricyclic antidepressants are also employed for chronic pruritus, especially when a component of depression is present. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus"</a>.)</p><p class="headingAnchor" id="H3756764328"><span class="h2">Limited disease</span></p><p class="headingAnchor" id="H2025666639"><span class="h3">Topical and intralesional corticosteroids</span><span class="headingEndMark"> — </span>For patients with a limited number of nodular lesions, we suggest superpotent topical corticosteroids (group 1  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)) as first-line therapy. Topical corticosteroids, such as <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> dipropionate 0.05% ointment, are applied under occlusion with plastic wrap once at nighttime for at least two to four weeks, though a longer course of treatment may be needed. Twice-daily application is recommended if occlusion is not used. Once control is achieved, topical corticosteroids can be tapered to once or twice weekly and continued as a long-term maintenance regimen.</p><p>The efficacy of topical corticosteroids for the treatment of PN has not been adequately evaluated in randomized trials. In a single small study including 12 patients with PN, a <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">betamethasone</a> valerate 0.1% medicated tape was more effective than an anti-itch moisturizer in reducing the intensity of pruritus and provided the additional benefit of preventing scratching [<a href="#rid53">53</a>].</p><p>Based upon clinical experience, intralesional injection of corticosteroids is effective in reducing pruritus and flattening the nodules. It may be a treatment option in patients who have only a few large PN lesions. <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">Triamcinolone</a> acetonide in concentrations of 5 to 20 mg/mL (based upon the size of the lesion and response to therapy) is injected in the lesions every four weeks until pruritus subsides and the nodules are flattened. Once significant improvement is noted, intralesional corticosteroids can be discontinued. Early recurrences can be treated with superpotent topical corticosteroids. (See  <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">"Intralesional corticosteroid injection"</a>.)</p><p class="headingAnchor" id="H2349049898"><span class="h3">Other topical therapies</span><span class="headingEndMark"> — </span>Other topical treatments that have been used with some success in patients with limited PN include topical <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a>, topical calcineurin inhibitors, and topical vitamin D analogues. None of these treatments has been adequately evaluated in randomized trials, and their use is based upon clinical experience and limited evidence from small observational studies.</p><p>Topical <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> may be a treatment option for motivated patients willing to adhere to a time-consuming schedule. Topical capsaicin 0.025% cream is applied four to six times per day for two weeks to up to several months, as tolerated.</p><p>Topical <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> exerts an analgesic and antipruritic effect by inducing the depletion of the neuropeptide substance P from local sensory nerve terminals in the skin, degeneration of epidermal nerve fibers, and desensitization of nociceptive nerve endings [<a href="#rid54">54,55</a>]. In one study, 33 patients with PN were treated with topical capsaicin 0.025 to 0.3% four to six times per day for 2 weeks up to 10 months [<a href="#rid56">56</a>]. Complete remission of pruritus was reported by all patients within 12 days of treatment. The nodules flattened and softened within two months in 24 patients. However, pruritus and skin nodules recurred in 16 patients upon discontinuation of treatment.</p><p>Other topical treatments reported as beneficial in small case series include topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, topical <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a>, topical vitamin D analogues (eg, <a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">calcipotriol</a>, tacalcitol), and a compounded mixture of topical <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, and <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> [<a href="#rid57">57-61</a>].</p><p class="headingAnchor" id="H1250466930"><span class="h2">Widespread or recalcitrant disease</span></p><p class="headingAnchor" id="H1835802151"><span class="h3">Phototherapy</span><span class="headingEndMark"> — </span>For patients with widespread disease and for those with recalcitrant disease that does not respond to topical or intralesional corticosteroids, we suggest narrowband ultraviolet B (NBUVB) phototherapy as first-line therapy if available and acceptable to the patient. NBUVB is administered two to three times weekly for up to 10 weeks in combination with topical corticosteroids. (See <a class="local">'Topical and intralesional corticosteroids'</a> above.)</p><p>Oral antihistamines, the tricyclic antidepressants <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">doxepin</a> or <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a>, or <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>/<a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> may be given as adjunctive treatment to control pruritus. Emollients and topical corticosteroids may also be used as needed.</p><p>Psoralen plus ultraviolet A (PUVA) can be an alternative form of phototherapy if NBUVB is not available. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a> and  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p>Limited evidence for efficacy of phototherapy, including NBUVB, systemic and bath/topical PUVA, ultraviolet A1 (UVA1), and monochromatic 308 nm excimer light, for the treatment of PN is derived from small observational studies and a single randomized trial [<a href="#rid62">62-67</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, 63 patients with PN were treated with topical PUVA [<a href="#rid66">66</a>]. Approximately 80 percent of patients improved after the first treatment cycle of two to four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, 22 patients with PN were randomized to use bath PUVA or bath PUVA plus targeted 308 nm excimer laser therapy. Six of 11 patients receiving bath PUVA alone and 7 of 10 receiving combined therapy had complete clearance [<a href="#rid64">64</a>]. Patients assigned to bath PUVA alone received an average of 20 treatment sessions, whereas patients assigned to combination therapy received an average of 10 bath PUVA sessions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NBUVB therapy was used to treat 10 patients with recalcitrant PN [<a href="#rid67">67</a>]. Improvement of skin lesions was reported in all patients after a median number of 16 weekly treatments.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monochromatic excimer light (308 nm) laser therapy induced partial or complete remission in 11 patients with PN after an average of 7.5 treatments [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A modified Goeckerman regimen was successfully used in a small study of four patients with recalcitrant PN who had failed previous treatment with standard NBUVB and broadband UVB therapy [<a href="#rid68">68</a>]. The regimen consisted of daily broadband UVB therapy followed by application of crude <a class="drug drug_general" data-topicid="8878" href="/z/d/drug information/8878.html" rel="external">coal tar</a> and topical corticosteroids under occlusion for four hours.</p><p></p><p class="headingAnchor" id="H1733895967"><span class="h3">Systemic therapies</span><span class="headingEndMark"> — </span>Patients with widespread or recalcitrant PN who fail to respond to phototherapy and those for whom phototherapy is not feasible may benefit from systemic treatments. <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a>, an interleukin (IL) 4 receptor inhibitor that inhibits downstream signaling of IL-4 and IL-13, is effective in reducing pruritus and resolving the skin lesions in patients with recalcitrant PN. (See <a class="local">'Dupilumab'</a> below.)</p><p>Other systemic treatments include systemic immunosuppressants, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and anticonvulsants [<a href="#rid69">69</a>]. These treatments are associated with potential significant toxicity, and their efficacy in patients with recalcitrant PN has not been established.</p><p class="headingAnchor" id="H1339030786"><span class="h4">Dupilumab</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> as first-line systemic treatment for recalcitrant PN in adults, especially in patients with underlying atopic dermatitis. Dupilumab is administered subcutaneously at an initial dose of 600 mg, followed by 300 mg every other week. Dupilumab was approved by the US Food and Drug Administration for the treatment of PN in adults in September 2022 [<a href="#rid70">70</a>].</p><p>Multiple reports and two randomized trials have documented the efficacy of <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> in reducing pruritus and resolving the skin lesions in patients with recalcitrant PN [<a href="#rid71">71-78</a>].</p><p>In a phase 3 trial that included 151 adult patients with PN treated with <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> 300 mg every two weeks or placebo, more patients in the dupilumab group than those in the placebo group achieved a ≥4 point reduction in the Worst Itch Numeric Rating Scale (WI-NRS) at 24 weeks (60 versus 18 percent, respectively) [<a href="#rid79">79</a>]. A second identical phase 3 trial that enrolled 160 patients showed a ≥4 point reduction in WI-NRS in 37 percent of patients taking dupilumab compared with 22 percent of patients taking placebo at week 12 [<a href="#rid79">79</a>]. In both trials, more patients in the dupilumab groups achieved an Investigator Global Assessment (IGA) score of clear/almost clear at 24 weeks compared with patients in the placebo groups (48 versus 18 percent; and 45 versus 16 percent, respectively). Adverse events occurred with similar frequency in all groups, were in most cases nonserious, and did not lead to treatment interruption. </p><p class="headingAnchor" id="H513342959"><span class="h4">Conventional immunosuppressants</span><span class="headingEndMark"> — </span>Low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (at a dose of 7.5 to 20 mg per week) or oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (at a dose of 3 to 5 mg/kg per day) may be beneficial in patients with recalcitrant PN, based upon clinical experience and a few small observational studies.</p><p>In a series of 13 patients with PN resistant to conventional therapies, low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (7.5 to 20 mg per week) was used for a minimum of six months. Ten patients achieved remission or marked improvement, measured as a reduction of the number and severity of skin lesions and pruritus [<a href="#rid80">80</a>].</p><p>Oral <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> has been shown to induce rapid control of pruritus in patients with recalcitrant PN [<a href="#rid81">81-83</a>]. In one study including 14 patients treated with cyclosporine 3 to 5 mg/kg per day, 10 patients reported a "very good response" after an average treatment time of 2.7 months [<a href="#rid82">82</a>]. In another report, eight patients with PN refractory to multiple topical and systemic therapies were treated with cyclosporine 2 to 4 mg/kg per day for 2 to 48 months; six achieved remission (absence of active or new lesions) after the first two to four weeks of treatment [<a href="#rid83">83</a>]. However, long-term treatment with cyclosporine is limited by adverse effects, such as elevation of blood pressure and serum creatinine.</p><p class="headingAnchor" id="H1125741386"><span class="h4">Thalidomide</span><span class="headingEndMark"> — </span>In selected patients with refractory disease, a trial of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> may be considered. However, thalidomide is teratogenic, and its use is associated with a dose-dependent risk of peripheral neuropathy that may be nonreversible, thromboembolism, and neutropenia. In the United States, patient and provider participation in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thalomidrems.com%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUr0y3syz4s%2FFGqvrL7LjgseikLArnHJzy1Ozp12%2FpMlm0&amp;TOPIC_ID=13667" target="_blank">THALOMID Risk Evaluation and Mitigation Strategy (REMS) program</a> is mandatory to obtain and dispense thalidomide.</p><p><a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a> is thought to have sedative, immunomodulatory, anti-inflammatory, and antiangiogenic properties [<a href="#rid84">84</a>]. Thalidomide has been used for the treatment of PN in both immunocompetent patients and in patients with HIV infection [<a href="#rid85">85-90</a>]. In a retrospective study, 42 patients with PN were treated with thalidomide at an average dose of 100 mg/day for an average of two years [<a href="#rid86">86</a>]. The average duration of thalidomide treatment before discontinuation due to neuropathy was 89 weeks (range: 1 week to 7.5 years). There was moderate to marked improvement in 50 percent of the patients; 12 patients showed only slight improvement or no effect.</p><p><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a> is a <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> analogue with more potent anti-inflammatory and antiangiogenic properties but with a reduced risk of peripheral neuropathy. Lenalidomide has been successfully used in a few patients with refractory PN [<a href="#rid91">91-93</a>].</p><p class="headingAnchor" id="H2982032762"><span class="h4">Other</span><span class="headingEndMark"> — </span>There are a few reports of successful treatment of recalcitrant PN with neuromodulators, such as <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> [<a href="#rid94">94,95</a>] and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> [<a href="#rid96">96-98</a>], the mu-opioid receptor antagonist <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> [<a href="#rid99">99</a>], and a combination of <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> and <a class="drug drug_general" data-topicid="8445" href="/z/d/drug information/8445.html" rel="external">fexofenadine</a> [<a href="#rid100">100</a>].</p><p>In an uncontrolled study including 20 patients (13 with PN) with intractable chronic pruritus, short-term treatment (&lt;2 weeks) with <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>, a neurokinin receptor 1 antagonist, induced complete or partial resolution of pruritus in 12 patients [<a href="#rid101">101</a>]. However, in a subsequent randomized, cross-over trial including 58 patients with chronic PN, four-week treatment with aprepitant 80 mg per day was no more effective than placebo in reducing pruritus intensity in both intention-to-treat and per protocol analysis [<a href="#rid102">102</a>]. Nonsevere adverse events occurred with equal frequency in the aprepitant and placebo groups.</p><p class="headingAnchor" id="H624977177"><span class="h1">INVESTIGATIONAL THERAPIES</span></p><p class="headingAnchor" id="H2372028041"><span class="h2">Nemolizumab</span><span class="headingEndMark"> — </span>Nemolizumab is a humanized antihuman interleukin (IL) 31 receptor monoclonal antibody that inhibits the binding of IL-31 to its receptor and subsequent signal transduction. In phase 2 and 3 clinical trials, nemolizumab showed efficacy in reducing pruritus associated with atopic dermatitis [<a href="#rid103">103-105</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of nemolizumab for the treatment of PN was evaluated in a randomized, phase 3 trial including 70 patients with moderate to severe PN (defined as presence of 20 or more nodules) and severe pruritus (defined as a mean score of at least 7 for the worst daily intensity of pruritus on a numerical rating scale of 0 to 10) for at least six months [<a href="#rid106">106</a>]. Patients received subcutaneous nemolizumab 0.5 mg/kg or placebo at baseline, week 4, and week 8. The primary outcome was the percent change from baseline in the peak pruritus score at week 4. Secondary outcomes included the reduction in the number of skin nodules at week 12. At week 4, the average peak pruritus score was reduced by 4.5 points (-53 percent) from baseline compared with a reduction by 1.7 points (-20 percent) in the placebo group (percentage difference 32.8, 95% CI -46.8 to -18.8). At week 12, the reduction in the mean lesion count was greater in the nemolizumab group than in the placebo group (least squares mean -12.6 versus -6.1 lesions, 95% CI -12.5 to -0.6). Adverse events associated with nemolizumab included abdominal pain, diarrhea, and musculoskeletal pain. A posthoc analysis of this trial showed that nemolizumab significantly reduced itch and improved sleep versus placebo within 48 hours [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a phase 3, randomized trial, 274 adult patients with moderate to severe PN were assigned to subcutaneous nemolizumab monotherapy (initial dose 60 mg followed by 30 or 60 mg every four weeks, based on body weight &lt;90 or ≥90 kg) or matching placebo for 16 weeks [<a href="#rid108">108</a>]. At week 16, more patients receiving nemolizumab than those receiving placebo achieved the primary endpoints of itch improvement ≥4 points from baseline on the Peak Pruritus Numerical Rating Scale (53 versus 21 percent, respectively) and an Investigator Global Assessment (IGA) score of 0/1 (clear/almost clear; 38 versus 11 percent, respectively). Fewer patients in the nemolizumab group received rescue therapy compared with the placebo group (5 versus 15 percent, respectively). Overall, adverse events occurred in 61 percent of patients in the nemolizumab group and 53 percent of those in the placebo group. Adverse events reported with higher frequency in the nemolizumab group were exacerbation/new onset of atopic dermatitis and peripheral or facial edema.</p><p></p><p class="bulletIndent1">Data on the long-term efficacy and safety of nemolizumab for PN are awaited.</p><p></p><p class="headingAnchor" id="H543184431"><span class="h2">Serlopitant</span><span class="headingEndMark"> — </span>In a randomized trial including 128 patients with chronic, treatment-refractory PN, serlopitant, a novel oral neurokinin 1 (NK1) antagonist, given at the dose of 5 mg orally once daily for eight weeks was more effective than placebo in reducing the average itch visual analog scale scores (least squares mean difference [serlopitant minus placebo] was -1 at week 4 and -1.7 at week 8) [<a href="#rid109">109</a>]. Adverse events in the serlopitant group included nasopharyngitis, diarrhea, and fatigue.</p><p class="headingAnchor" id="H21099351"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>PN is a chronic and often intractable disease that may last for years, with a profound impact on the patient's quality of life. Complete resolution of lesions is rare, even after the itch-scratch cycle has been successfully interrupted. Recurrence is common.</p><p class="headingAnchor" id="H833962740"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/128958.html" rel="external">"Society guideline links: Prurigo nodularis"</a>.)</p><p class="headingAnchor" id="H21099358"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Prurigo nodularis (PN) is a chronic skin disorder characterized by multiple firm, itchy nodules typically localized to the extensor surface of the extremities  (<a class="graphic graphic_picture graphicRef66268 graphicRef53475 graphicRef86816 graphicRef86817" href="/z/d/graphic/66268.html" rel="external">picture 1C-E, 1G</a>). Pruritus is always severe and distressing; it can be paroxysmal, sporadic, or continuous and is worsened by heat, sweating, or irritation from clothing. (See <a class="local">'Introduction'</a> above and <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of PN is clinical, based upon a history of chronic, severe pruritus and the clinical finding of characteristic excoriated, nodular lesions symmetrically distributed. Cutaneous and systemic causes of chronic pruritus should be investigated. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Potential causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of PN is difficult and requires a multifaceted approach, involving patient education to adopt skin care measures to reduce skin irritation and scratching, symptomatic treatment of pruritus, and topical or systemic therapies aimed at interrupting the itch-scratch cycle and flattening the skin lesions. (See <a class="local">'Management'</a> above and <a class="local">'Symptomatic control of pruritus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Limited number of nodular lesions</strong> – For patients with a limited number of nodular lesions, we suggest superpotent topical corticosteroids (group 1  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)) as first-line therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Intralesional injection of corticosteroids may be an additional or alternative treatment modality for patients with very few lesions. Sedating antihistamines, such <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a>, or others, are routinely used. (See <a class="local">'Limited disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Widespread/recalcitrant disease</strong> – For patients with widespread or recalcitrant disease, we suggest phototherapy with narrowband ultraviolet B (NBUVB) as first-line therapy if available and acceptable to the patient (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Phototherapy'</a> above.)</p><p></p><p class="bulletIndent2">For patients for whom phototherapy is not feasible, we suggest treatment with <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> rather than other systemic agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other systemic treatments include <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. (See <a class="local">'Systemic therapies'</a> above and <a class="local">'Dupilumab'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005; 46:211.</a></li><li><a class="nounderline abstract_t">Zeidler C, Tsianakas A, Pereira M, et al. Chronic Prurigo of Nodular Type: A Review. Acta Derm Venereol 2018; 98:173.</a></li><li><a class="nounderline abstract_t">Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: Pathogenesis and management. J Am Acad Dermatol 2020; 83:1567.</a></li><li><a class="nounderline abstract_t">Huang AH, Canner JK, Khanna R, et al. Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases. J Invest Dermatol 2020; 140:480.</a></li><li><a class="nounderline abstract_t">Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol 2013; 27:550.</a></li><li><a class="nounderline abstract_t">Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32:1059.</a></li><li><a class="nounderline abstract_t">Boozalis E, Tang O, Patel S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol 2018; 79:714.</a></li><li><a class="nounderline abstract_t">Zancanaro PC, McGirt LY, Mamelak AJ, et al. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol 2006; 54:581.</a></li><li><a class="nounderline abstract_t">Magand F, Nacher M, Cazorla C, et al. Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana. Trans R Soc Trop Med Hyg 2011; 105:401.</a></li><li><a class="nounderline abstract_t">Harris B, Harris K, Penneys NS. Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis. J Am Acad Dermatol 1992; 26:56.</a></li><li><a class="nounderline abstract_t">Liang Y, Marcusson JA, Johansson O. Light and electron microscopic immunohistochemical observations of p75 nerve growth factor receptor-immunoreactive dermal nerves in prurigo nodularis. Arch Dermatol Res 1999; 291:14.</a></li><li><a class="nounderline abstract_t">Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia. Arch Dermatol Res 2002; 293:614.</a></li><li><a class="nounderline abstract_t">Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7:535.</a></li><li><a class="nounderline abstract_t">Liang Y, Marcusson JA, Jacobi HH, et al. Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J Cutan Pathol 1998; 25:189.</a></li><li><a class="nounderline abstract_t">Perez GL, Peters MS, Reda AM, et al. Mast cells, neutrophils, and eosinophils in prurigo nodularis. Arch Dermatol 1993; 129:861.</a></li><li><a class="nounderline abstract_t">Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol 2011; 165:85.</a></li><li><a class="nounderline abstract_t">Bobko S, Zeidler C, Osada N, et al. Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions. Acta Derm Venereol 2016; 96:404.</a></li><li><a class="nounderline abstract_t">Zeidler C, Ständer S. The pathogenesis of Prurigo nodularis--'Super-Itch' in exploration. Eur J Pain 2016; 20:37.</a></li><li><a class="nounderline abstract_t">Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol 2011; 165:990.</a></li><li><a class="nounderline abstract_t">Belzberg M, Alphonse MP, Brown I, et al. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization. J Invest Dermatol 2021; 141:2208.</a></li><li><a class="nounderline abstract_t">Parthasarathy V, Cravero K, Xu L, et al. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis. J Am Acad Dermatol 2023; 88:1101.</a></li><li><a class="nounderline abstract_t">Zhong W, Wu X, Zhang W, et al. Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis. Acta Derm Venereol 2019; 99:579.</a></li><li><a class="nounderline abstract_t">Furue M, Yamamura K, Kido-Nakahara M, et al. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy 2018; 73:29.</a></li><li><a class="nounderline abstract_t">Deng J, Liao V, Parthasarathy V, et al. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab. JAMA Dermatol 2023; 159:977.</a></li><li><a class="nounderline abstract_t">Weigelt N, Metze D, Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol 2010; 37:578.</a></li><li><a class="nounderline abstract_t">Powell AM, Albert S, Gratian MJ, et al. Pemphigoid nodularis (non-bullous): a clinicopathological study of five cases. Br J Dermatol 2002; 147:343.</a></li><li><a class="nounderline abstract_t">Mattila JO, Vornanen M, Katila ML. Histopathological and bacteriological findings in prurigo nodularis. Acta Derm Venereol 1997; 77:49.</a></li><li><a class="nounderline abstract_t">Rowland Payne CM, Wilkinson JD, McKee PH, et al. Nodular prurigo--a clinicopathological study of 46 patients. Br J Dermatol 1985; 113:431.</a></li><li><a class="nounderline abstract_t">Miyauchi H, Uehara M. Follicular occurrence of prurigo nodularis. J Cutan Pathol 1988; 15:208.</a></li><li><a class="nounderline abstract_t">Pereira MP, Hoffmann V, Weisshaar E, et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol 2020; 34:2373.</a></li><li><a class="nounderline abstract_t">Jacob CI, Patten SF. Strongyloides stercoralis infection presenting as generalized prurigo nodularis and lichen simplex chronicus. J Am Acad Dermatol 1999; 41:357.</a></li><li><a class="nounderline abstract_t">Shelnitz LS, Paller AS. Hodgkin's disease manifesting as prurigo nodularis. Pediatr Dermatol 1990; 7:136.</a></li><li><a class="nounderline abstract_t">Torchia D, Caproni M, Del Bianco E, et al. Linear IgA disease presenting as prurigo nodularis. Br J Dermatol 2006; 155:479.</a></li><li><a class="nounderline abstract_t">Savoia F, Casadio C, Tabanelli M, et al. Prurigo nodularis as the first manifestation of a chronic autoimmune cholestatic hepatitis. Int J Dermatol 2011; 50:1588.</a></li><li><a class="nounderline abstract_t">Wu TP, Miller K, Cohen DE, Stein JA. Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skin. J Am Acad Dermatol 2013; 69:426.</a></li><li><a class="nounderline abstract_t">Tanaka M, Aiba S, Matsumura N, et al. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology 1995; 190:269.</a></li><li><a class="nounderline abstract_t">Zelickson BD, McEvoy MT, Fransway AF. Patch testing in prurigo nodularis. Contact Dermatitis 1989; 20:321.</a></li><li><a class="nounderline abstract_t">Schneider G, Hockmann J, Ständer S, et al. Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris: results of a case-control study. Br J Dermatol 2006; 154:61.</a></li><li><a class="nounderline abstract_t">Dazzi C, Erma D, Piccinno R, et al. Psychological factors involved in prurigo nodularis: A pilot study. J Dermatolog Treat 2011; 22:211.</a></li><li><a class="nounderline abstract_t">Jørgensen KM, Egeberg A, Gislason GH, et al. Anxiety, depression and suicide in patients with prurigo nodularis. J Eur Acad Dermatol Venereol 2017; 31:e106.</a></li><li><a class="nounderline abstract_t">Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: Epidemiology and clinical features. J Am Acad Dermatol 2020; 83:1559.</a></li><li><a class="nounderline abstract_t">Joel MZ, Hydol-Smith J, Kambala A, et al. Prevalence and comorbidity burden of prurigo nodularis in United States adults enrolled in the All of Us research program. J Am Acad Dermatol 2023; 89:1056.</a></li><li><a class="nounderline abstract_t">Choragudi S, Yosipovitch G. Prurigo nodularis is highly linked with neural sensitization disorders of pain among hospitalized adults in the United States - National Inpatient Sample 2016-2019. Br J Dermatol 2023; 189:240.</a></li><li><a class="nounderline abstract_t">Ständer HF, Elmariah S, Zeidler C, et al. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol 2020; 82:460.</a></li><li><a class="nounderline abstract_t">Saray Y, Seçkin D, Bilezikçi B. Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol 2006; 20:679.</a></li><li><a class="nounderline abstract_t">Zhang W, Liu Y, Li C. Generalised nodules in pemphigoid nodularis. Lancet 2017; 389:1930.</a></li><li><a class="nounderline abstract_t">Tashiro H, Arai H, Hashimoto T, et al. Pemphigoid nodularis: two case studies and analysis of autoantibodies before and after the development of generalized blistering. J Nippon Med Sch 2005; 72:60.</a></li><li><a class="nounderline abstract_t">Kwiek B, Schwartz RA. Keratoacanthoma (KA): An update and review. J Am Acad Dermatol 2016; 74:1220.</a></li><li><a class="nounderline abstract_t">Kim WB, Alavi A, Pope E, Walsh S. Epidermolysis Bullosa Pruriginosa: Case Series and Review of the Literature. Int J Low Extrem Wounds 2015; 14:196.</a></li><li><a class="nounderline abstract_t">Frane AV. Comment on: epidermolysis bullosa pruriginosa: a systematic review exploring genotype-phenotype correlation. Am J Clin Dermatol 2015; 16:335.</a></li><li><a class="nounderline abstract_t">Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol 2021; 84:747.</a></li><li><a class="nounderline abstract_t">Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol 2019; 80:756.</a></li><li><a class="nounderline abstract_t">Saraceno R, Chiricozzi A, Nisticò SP, et al. An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis. J Dermatolog Treat 2010; 21:363.</a></li><li><a class="nounderline abstract_t">Nolano M, Simone DA, Wendelschafer-Crabb G, et al. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999; 81:135.</a></li><li><a class="nounderline abstract_t">Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010; 11:579.</a></li><li><a class="nounderline abstract_t">Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44:471.</a></li><li><a class="nounderline abstract_t">Wong SS, Goh CL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis. Arch Dermatol 2000; 136:807.</a></li><li><a class="nounderline abstract_t">Ständer S, Schürmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2006; 2:213.</a></li><li><a class="nounderline abstract_t">Katayama I, Miyazaki Y, Nishioka K. Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo. Br J Dermatol 1996; 135:237.</a></li><li><a class="nounderline abstract_t">Siepmann D, Lotts T, Blome C, et al. Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial. Dermatology 2013; 227:353.</a></li><li><a class="nounderline abstract_t">Lee HG, Grossman SK, Valdes-Rodriguez R, et al. Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability. J Am Acad Dermatol 2017; 76:760.</a></li><li><a class="nounderline abstract_t">Saraceno R, Nisticò SP, Capriotti E, et al. Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis. Photodermatol Photoimmunol Photomed 2008; 24:43.</a></li><li><a class="nounderline abstract_t">Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol 2010; 35:549.</a></li><li><a class="nounderline abstract_t">Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol 2011; 25:799.</a></li><li><a class="nounderline abstract_t">Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24:19.</a></li><li><a class="nounderline abstract_t">Karvonen J, Hannuksela M. Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo. Acta Derm Venereol Suppl (Stockh) 1985; 120:53.</a></li><li><a class="nounderline abstract_t">Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. J Dermatol 2007; 34:691.</a></li><li><a class="nounderline abstract_t">Sorenson E, Levin E, Koo J, Berger TG. Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis. J Am Acad Dermatol 2015; 72:e40.</a></li><li><a class="nounderline abstract_t">Tsianakas A, Zeidler C, Ständer S. Prurigo Nodularis Management. Curr Probl Dermatol 2016; 50:94.</a></li><li class="breakAll">Dupixent (dupilumab) injection, for subcutaneous use. US FDA approved product information; Tarrytown, NY: Regeneron Pharmaceuticals, Inc; September 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s044lbl.pdf (Accessed on November 07, 2022).</li><li><a class="nounderline abstract_t">Mollanazar NK, Elgash M, Weaver L, et al. Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis. JAMA Dermatol 2019; 155:121.</a></li><li><a class="nounderline abstract_t">Beck KM, Yang EJ, Sekhon S, et al. Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatol 2019; 155:118.</a></li><li><a class="nounderline abstract_t">Ferrucci S, Tavecchio S, Berti E, Angileri L. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. J Dermatolog Treat 2021; 32:453.</a></li><li><a class="nounderline abstract_t">Giura MT, Viola R, Fierro MT, et al. Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatol Ther 2020; 33:e13201.</a></li><li><a class="nounderline abstract_t">Holm JG, Agner T, Sand C, Thomsen SF. Dupilumab for prurigo nodularis: Case series and review of the literature. Dermatol Ther 2020; 33:e13222.</a></li><li><a class="nounderline abstract_t">Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur Acad Dermatol Venereol 2020; 34:e74.</a></li><li><a class="nounderline abstract_t">Georgakopoulos JR, Croitoru D, Felfeli T, et al. Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. J Am Acad Dermatol 2021; 85:1049.</a></li><li><a class="nounderline abstract_t">Fang HY, Lian CH. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study. J Dermatol 2023; 50:1084.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med 2023; 29:1180.</a></li><li><a class="nounderline abstract_t">Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol 2014; 39:468.</a></li><li><a class="nounderline abstract_t">Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporin. Br J Dermatol 1995; 132:795.</a></li><li><a class="nounderline abstract_t">Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges 2008; 6:941.</a></li><li><a class="nounderline abstract_t">Wiznia LE, Callahan SW, Cohen DE, Orlow SJ. Rapid improvement of prurigo nodularis with cyclosporine treatment. J Am Acad Dermatol 2018; 78:1209.</a></li><li><a class="nounderline abstract_t">Wu JJ, Huang DB, Pang KR, et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005; 153:254.</a></li><li><a class="nounderline abstract_t">Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008; 7:769.</a></li><li><a class="nounderline abstract_t">Andersen TP, Fogh K. Thalidomide in 42 patients with prurigo nodularis Hyde. Dermatology 2011; 223:107.</a></li><li><a class="nounderline abstract_t">Lan CC, Lin CL, Wu CS, et al. Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide. J Dermatol 2007; 34:237.</a></li><li><a class="nounderline abstract_t">Taefehnorooz H, Truchetet F, Barbaud A, et al. Efficacy of thalidomide in the treatment of prurigo nodularis. Acta Derm Venereol 2011; 91:344.</a></li><li><a class="nounderline abstract_t">Maurer T, Poncelet A, Berger T. Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. Arch Dermatol 2004; 140:845.</a></li><li><a class="nounderline abstract_t">Lim VM, Maranda EL, Patel V, et al. A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. Dermatol Ther (Heidelb) 2016; 6:397.</a></li><li><a class="nounderline abstract_t">Kanavy H, Bahner J, Korman NJ. Treatment of refractory prurigo nodularis with lenalidomide. Arch Dermatol 2012; 148:794.</a></li><li><a class="nounderline abstract_t">Liu H, Gaspari AA, Schleichert R. Use of lenalidomide in treating refractory prurigo nodularis. J Drugs Dermatol 2013; 12:360.</a></li><li><a class="nounderline abstract_t">Ossorio-García L, Jiménez-Gallo D, Rodríguez-Mateos ME, et al. Treatment of prurigo nodularis with lenalidomide. Dermatol Ther 2017; 30.</a></li><li><a class="nounderline abstract_t">Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther 2010; 23:194.</a></li><li><a class="nounderline abstract_t">Dereli T, Karaca N, Inanir I, Oztürk G. Gabapentin for the treatment of recalcitrant chronic prurigo nodularis. Eur J Dermatol 2008; 18:85.</a></li><li><a class="nounderline abstract_t">Mazza M, Guerriero G, Marano G, et al. Treatment of prurigo nodularis with pregabalin. J Clin Pharm Ther 2013; 38:16.</a></li><li><a class="nounderline abstract_t">Asplund M, Calling S, Spirén A, Svedman C. [Prurigo nodularis--pregabalin can be considered for more severe symptoms]. Lakartidningen 2015; 112.</a></li><li><a class="nounderline abstract_t">Imai K, Kishimoto M, Tsujimoto T, et al. Successful treatment of chronic intractable itching using oral pregabalin in a patient with diabetes and systemic prurigo nodularis: a case report of an iliopsoas muscle abscess. Intern Med 2013; 52:2629.</a></li><li><a class="nounderline abstract_t">Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63:680.</a></li><li><a class="nounderline abstract_t">Shintani T, Ohata C, Koga H, et al. Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Dermatol Ther 2014; 27:135.</a></li><li><a class="nounderline abstract_t">Ständer S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5:e10968.</a></li><li><a class="nounderline abstract_t">Tsianakas A, Zeidler C, Riepe C, et al. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). Acta Derm Venereol 2019; 99:379.</a></li><li><a class="nounderline abstract_t">Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 2020; 145:173.</a></li><li><a class="nounderline abstract_t">Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol 2018; 142:1121.</a></li><li><a class="nounderline abstract_t">Ruzicka T, Hanifin JM, Furue M, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med 2017; 376:826.</a></li><li><a class="nounderline abstract_t">Ständer S, Yosipovitch G, Legat FJ, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med 2020; 382:706.</a></li><li><a class="nounderline abstract_t">Ständer S, Yosipovitch G, Lacour JP, et al. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol 2022; 36:1820.</a></li><li><a class="nounderline abstract_t">Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. N Engl J Med 2023; 389:1579.</a></li><li><a class="nounderline abstract_t">Ständer S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol 2019; 80:1395.</a></li></ol></div><div id="topicVersionRevision">Topic 13667 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16197418" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prurigo nodularis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29135018" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chronic Prurigo of Nodular Type: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32461078" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prurigo nodularis: Pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31421126" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22364653" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28857299" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29733939" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ethnic differences and comorbidities of 909 prurigo nodularis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16546578" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21621233" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732336" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025723" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Light and electron microscopic immunohistochemical observations of p75 nerve growth factor receptor-immunoreactive dermal nerves in prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11875644" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin -- an exploration of the cause of neurohyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791143" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The neurobiology of itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609137" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323307" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mast cells, neutrophils, and eosinophils in prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21410670" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26338533" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416433" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The pathogenesis of Prurigo nodularis--'Super-Itch' in exploration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21711341" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33771530" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36806647" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30809683" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28670717" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37556125" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002240" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174109" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pemphigoid nodularis (non-bullous): a clinicopathological study of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9059678" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Histopathological and bacteriological findings in prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4063179" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Nodular prurigo--a clinicopathological study of 46 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3183136" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Follicular occurrence of prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32078192" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426933" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Strongyloides stercoralis infection presenting as generalized prurigo nodularis and lichen simplex chronicus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2359730" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hodgkin's disease manifesting as prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16882196" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Linear IgA disease presenting as prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22098015" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prurigo nodularis as the first manifestation of a chronic autoimmune cholestatic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664628" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7655104" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2766699" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Patch testing in prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403095" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris: results of a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20666670" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Psychological factors involved in prurigo nodularis: A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27505149" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Anxiety, depression and suicide in patients with prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32454098" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prurigo nodularis: Epidemiology and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37422017" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prevalence and comorbidity burden of prurigo nodularis in United States adults enrolled in the All of Us research program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37067913" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prurigo nodularis is highly linked with neural sensitization disorders of pain among hospitalized adults in the United States - National Inpatient Sample 2016-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31310842" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnostic and treatment algorithm for chronic nodular prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16836495" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acquired perforating dermatosis: clinicopathological features in twenty-two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28215664" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Generalised nodules in pemphigoid nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15834209" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pemphigoid nodularis: two case studies and analysis of autoantibodies before and after the development of generalized blistering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26853179" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Keratoacanthoma (KA): An update and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25694436" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Epidermolysis Bullosa Pruriginosa: Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26187371" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comment on: epidermolysis bullosa pruriginosa: a systematic review exploring genotype-phenotype correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682025" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30261199" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A systematic review of evidence-based treatments for prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536273" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10353501" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20400377" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11209117" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of prurigo nodularis with topical capsaicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10871962" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of Prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18360595" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of pruritic diseases with topical calcineurin inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8881666" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Topical vitamin D3 (tacalcitol) for steroid-resistant prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24281309" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28325395" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201357" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886961" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Phototherapy of generalized prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946583" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201353" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy of UVA1 phototherapy in 230 patients with various skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3869416" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908139" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25497953" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27578077" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Prurigo Nodularis Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27578077" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prurigo Nodularis Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30427989" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30427994" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dupilumab Treatment for Generalized Prurigo Nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31442084" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31856368" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy of dupilumab in prurigo nodularis in elderly patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31917498" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Dupilumab for prurigo nodularis: Case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31529718" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33617911" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37088954" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37142763" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24825138" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prurigo nodularis: retrospective study of 13 cases managed with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7772488" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nodular prurigo responds to cyclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445069" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438756" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Rapid improvement of prurigo nodularis with cyclosporine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086735" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Thalidomide: dermatological indications, mechanisms of action and side-effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720694" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A case series of 48 patients treated with thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21952556" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Thalidomide in 42 patients with prurigo nodularis Hyde.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17352720" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21279302" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Efficacy of thalidomide in the treatment of prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262695" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27289372" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801610" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Treatment of refractory prurigo nodularis with lenalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545923" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Use of lenalidomide in treating refractory prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27891738" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of prurigo nodularis with lenalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20415827" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086601" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Gabapentin for the treatment of recalcitrant chronic prurigo nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013514" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Treatment of prurigo nodularis with pregabalin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671429" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : [Prurigo nodularis--pregabalin can be considered for more severe symptoms].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24292753" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Successful treatment of chronic intractable itching using oral pregabalin in a patient with diabetes and systemic prurigo nodularis: a case report of an iliopsoas muscle abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20462660" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Antipruritic treatment with systemicμ-opioid receptor antagonists: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24102897" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20532044" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30653242" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31449914" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29753033" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28249150" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32074418" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35766128" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37888917" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30894279" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
